Literature DB >> 33691644

A new rapid diagnostic system with ambient mass spectrometry and machine learning for colorectal liver metastasis.

Sho Kiritani1, Kentaro Yoshimura2, Junichi Arita1, Takashi Kokudo1, Hiroyuki Hakoda1, Meguri Tanimoto1, Takeaki Ishizawa1, Nobuhisa Akamatsu1, Junichi Kaneko1, Sen Takeda2, Kiyoshi Hasegawa3.   

Abstract

BACKGROUND: Probe electrospray ionization-mass spectrometry (PESI-MS) can rapidly visualize mass spectra of small, surgically obtained tissue samples, and is a promising novel diagnostic tool when combined with machine learning which discriminates malignant spectrum patterns from others. The present study was performed to evaluate the utility of this device for rapid diagnosis of colorectal liver metastasis (CRLM).
METHODS: A prospectively planned study using retrospectively obtained tissues was performed. In total, 103 CRLM samples and 80 non-cancer liver tissues cut from surgically extracted specimens were analyzed using PESI-MS. Mass spectra obtained by PESI-MS were classified into cancer or non-cancer groups by using logistic regression, a kind of machine learning. Next, to identify the exact molecules responsible for the difference between CRLM and non-cancerous tissues, we performed liquid chromatography-electrospray ionization-MS (LC-ESI-MS), which visualizes sample molecular composition in more detail.
RESULTS: This diagnostic system distinguished CRLM from non-cancer liver parenchyma with an accuracy rate of 99.5%. The area under the receiver operating characteristic curve reached 0.9999. LC-ESI-MS analysis showed higher ion intensities of phosphatidylcholine and phosphatidylethanolamine in CRLM than in non-cancer liver parenchyma (P < 0.01, respectively). The proportion of phospholipids categorized as monounsaturated fatty acids was higher in CRLM (37.2%) than in non-cancer liver parenchyma (10.7%; P < 0.01).
CONCLUSION: The combination of PESI-MS and machine learning distinguished CRLM from non-cancer tissue with high accuracy. Phospholipids categorized as monounsaturated fatty acids contributed to the difference between CRLM and normal parenchyma and might also be a useful diagnostic biomarker and therapeutic target for CRLM.

Entities:  

Keywords:  Colorectal cancer; Liver metastasis; Machine learning; Mass spectrometry; Rapid diagnosis

Mesh:

Year:  2021        PMID: 33691644      PMCID: PMC7945316          DOI: 10.1186/s12885-021-08001-5

Source DB:  PubMed          Journal:  BMC Cancer        ISSN: 1471-2407            Impact factor:   4.430


  30 in total

1.  Construction of mass spectra database and diagnosis algorithm for head and neck squamous cell carcinoma.

Authors:  Kei Ashizawa; Kentaro Yoshimura; Hisashi Johno; Tomohiro Inoue; Ryohei Katoh; Satoshi Funayama; Kaname Sakamoto; Sen Takeda; Keisuke Masuyama; Tomokazu Matsuoka; Hiroki Ishii
Journal:  Oral Oncol       Date:  2017-11-10       Impact factor: 5.337

2.  Real-time diagnosis of chemically induced hepatocellular carcinoma using a novel mass spectrometry-based technique.

Authors:  Kentaro Yoshimura; Mridul Kanti Mandal; Michio Hara; Hideki Fujii; Lee Chuin Chen; Kunio Tanabe; Kenzo Hiraoka; Sen Takeda
Journal:  Anal Biochem       Date:  2013-07-11       Impact factor: 3.365

3.  Contrast-enhanced intraoperative ultrasonography during hepatectomies for colorectal cancer liver metastases.

Authors:  Guido Torzilli; Daniele Del Fabbro; Angela Palmisano; Matteo Donadon; Paolo Bianchi; Massimo Roncalli; Luca Balzarini; Marco Montorsi
Journal:  J Gastrointest Surg       Date:  2005-11       Impact factor: 3.452

4.  Resection margin and survival in 2368 patients undergoing hepatic resection for metastatic colorectal cancer: surgical technique or biologic surrogate?

Authors:  Eran Sadot; Bas Groot Koerkamp; Julie N Leal; Jinru Shia; Mithat Gonen; Peter J Allen; Ronald P DeMatteo; T Peter Kingham; Nancy Kemeny; Leslie H Blumgart; William R Jarnagin; Michael I DʼAngelica
Journal:  Ann Surg       Date:  2015-09       Impact factor: 12.969

5.  Accumulated phosphatidylcholine (16:0/16:1) in human colorectal cancer; possible involvement of LPCAT4.

Authors:  Nobuya Kurabe; Takahiro Hayasaka; Mikako Ogawa; Noritaka Masaki; Yoshimi Ide; Michihiko Waki; Toshio Nakamura; Kiyotaka Kurachi; Tomoaki Kahyo; Kazuya Shinmura; Yutaka Midorikawa; Yasuyuki Sugiyama; Mitsutoshi Setou; Haruhiko Sugimura
Journal:  Cancer Sci       Date:  2013-07-30       Impact factor: 6.716

6.  MALDI-based imaging mass spectrometry revealed abnormal distribution of phospholipids in colon cancer liver metastasis.

Authors:  Shuichi Shimma; Yuki Sugiura; Takahiro Hayasaka; Yutaka Hoshikawa; Tetsuo Noda; Mitsutoshi Setou
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2007-02-28       Impact factor: 3.205

7.  ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.

Authors:  E Van Cutsem; A Cervantes; R Adam; A Sobrero; J H Van Krieken; D Aderka; E Aranda Aguilar; A Bardelli; A Benson; G Bodoky; F Ciardiello; A D'Hoore; E Diaz-Rubio; J-Y Douillard; M Ducreux; A Falcone; A Grothey; T Gruenberger; K Haustermans; V Heinemann; P Hoff; C-H Köhne; R Labianca; P Laurent-Puig; B Ma; T Maughan; K Muro; N Normanno; P Österlund; W J G Oyen; D Papamichael; G Pentheroudakis; P Pfeiffer; T J Price; C Punt; J Ricke; A Roth; R Salazar; W Scheithauer; H J Schmoll; J Tabernero; J Taïeb; S Tejpar; H Wasan; T Yoshino; A Zaanan; D Arnold
Journal:  Ann Oncol       Date:  2016-07-05       Impact factor: 32.976

8.  SCD1 inhibition causes cancer cell death by depleting mono-unsaturated fatty acids.

Authors:  Paul Mason; Beirong Liang; Lingyun Li; Trisha Fremgen; Erin Murphy; Angela Quinn; Stephen L Madden; Hans-Peter Biemann; Bing Wang; Aharon Cohen; Svetlana Komarnitsky; Kate Jancsics; Brad Hirth; Christopher G F Cooper; Edward Lee; Sean Wilson; Roy Krumbholz; Steven Schmid; Yibin Xiang; Michael Booker; James Lillie; Kara Carter
Journal:  PLoS One       Date:  2012-03-22       Impact factor: 3.240

Review 9.  Advances in Lipidomics for Cancer Biomarkers Discovery.

Authors:  Francesca Perrotti; Consuelo Rosa; Ilaria Cicalini; Paolo Sacchetta; Piero Del Boccio; Domenico Genovesi; Damiana Pieragostino
Journal:  Int J Mol Sci       Date:  2016-11-28       Impact factor: 5.923

10.  Colorectal cancer liver metastases - a population-based study on incidence, management and survival.

Authors:  Jennie Engstrand; Henrik Nilsson; Cecilia Strömberg; Eduard Jonas; Jacob Freedman
Journal:  BMC Cancer       Date:  2018-01-15       Impact factor: 4.430

View more
  5 in total

1.  Utility of mass spectrometry and artificial intelligence for differentiating primary lung adenocarcinoma and colorectal metastatic pulmonary tumor.

Authors:  Wataru Shigeeda; Ryuichi Yosihimura; Yuji Fujita; Hidekazu Saiki; Hiroyuki Deguchi; Makoto Tomoyasu; Satoshi Kudo; Yuka Kaneko; Hironaga Kanno; Yoshihiro Inoue; Hajime Saito
Journal:  Thorac Cancer       Date:  2021-11-23       Impact factor: 3.500

Review 2.  Artificial intelligence in the diagnosis and management of colorectal cancer liver metastases.

Authors:  Gianluca Rompianesi; Francesca Pegoraro; Carlo Dl Ceresa; Roberto Montalti; Roberto Ivan Troisi
Journal:  World J Gastroenterol       Date:  2022-01-07       Impact factor: 5.742

Review 3.  The phospholipid membrane compositions of bacterial cells, cancer cell lines and biological samples from cancer patients.

Authors:  Kira L F Hilton; Chandni Manwani; Jessica E Boles; Lisa J White; Sena Ozturk; Michelle D Garrett; Jennifer R Hiscock
Journal:  Chem Sci       Date:  2021-09-28       Impact factor: 9.825

4.  Evaluation of CSTB and DMBT1 expression in saliva of gastric cancer patients and controls.

Authors:  Maryam Koopaie; Marjan Ghafourian; Soheila Manifar; Shima Younespour; Mansour Davoudi; Sajad Kolahdooz; Mohammad Shirkhoda
Journal:  BMC Cancer       Date:  2022-04-30       Impact factor: 4.638

Review 5.  Applications of Artificial Intelligence in Screening, Diagnosis, Treatment, and Prognosis of Colorectal Cancer.

Authors:  Hang Qiu; Shuhan Ding; Jianbo Liu; Liya Wang; Xiaodong Wang
Journal:  Curr Oncol       Date:  2022-03-07       Impact factor: 3.677

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.